Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy and Bevacizumab With or Without Radiofrequency Ablation in Treating Unresectable Liver Metastases in Patients With Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Unresectable liver metastases secondary to colorectal adenocarcinoma, including:~  * Metastases that cannot be radically resected due to size, location, or number of deposits~ * Metastases invading right and left branches of hepatic artery or portal vein~ * Metastases extended to the 3 main hepatic veins~* No detectable extra-hepatic disease~* Fewer than 10 metastatic deposits on liver~* Total metastatic involvement of liver no more than 50%~* Adequate treatment of all metastatic lesions deemed possible either by radiofrequency interstitial ablation (RFA) alone or by a combination of resection of resectable lesions and RFA of the remaining unresectable lesions~  * Maximum diameter of 4 cm for lesions to be treated with RFA~ * No maximum diameter of lesions to be resected as long as negative resection margins are obtainable~* If synchronous liver metastases, must have undergone prior resection of primary tumor~PATIENT CHARACTERISTICS:~Age~* 18 to 80~Performance status~* WHO 0-1~Life expectancy~* Not specified~Hematopoietic~* Absolute neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~* No bleeding disorder or coagulopathy or need for full-dose anticoagulation~Hepatic~* Bilirubin less than 3 times upper limit of normal (ULN)~* Alkaline phosphatase less than 3 times ULN~Renal~* Creatinine less than 2 times ULN~* Protein \< 0.5 g/24 hr urine collection if proteinuria positive by dipstick~Cardiovascular~* No uncontrolled congestive heart failure~* No uncontrolled angina pectoris~* No uncontrolled hypertension~* No uncontrolled arrhythmia~* No myocardial infarction within the past 12 months~* No cerebrovascular accident or transient ischemic attack within the past 6 months~Other~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No greater than grade 1 peripheral neuropathy~* No significant neurologic or psychiatric disorder~* No active infection~* No contraindication to the use of fluorouracil, leucovorin calcium, oxaliplatin, or bevacizumab~* No other malignancy within the past 10 years except nonmelanoma skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy except for metastatic disease confined to the liver~  * Prior fluorouracil, leucovorin calcium, and oxaliplatin allowed if administered for at least 3 courses (2 weeks each) but no longer than 3 months with at least stabilization of disease achieved~* Prior adjuvant chemotherapy for primary cancer allowed except for patients who received oxaliplatin and have been diagnosed with metastatic disease within 12 months after completion of adjuvant treatment~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* More than 28 days since major surgery or open biopsy past 28 days~* More than 28 days since significant traumatic injury~Other~* No other concurrent investigational treatment~* No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues